Patents
US 12735726 B2: Targeting deltaFosB for treatment of dyskinesia
- Granted
- 2026-09-15
- Filed
- 2020-11-02 application 17755504
- Type
- Utility · 14 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
Compositions, non-viral vectors, recombinant viruses, and recombinant viral vectors for inhibiting ΔFosB expression or activity in a cell and for treating dyskinesia in a subject (e.g., a human patient having Parkinson's disease and Levodopa-induced dyskinesia) include a nucleic acid sequence encoding a shRNA specific for ΔFosB. Methods of using these compositions, non-viral vectors, recombinant viruses, and recombinant viral vectors are also described herein. These compositions, non-viral vectors, recombinant viruses, and recombinant viral vectors and methods of use provide novel therapies for dyskinesia based on the reduction of ΔFosB expression and/or activity.
Source: PTBLXML, file of 2026-09-15 (ipgb20260915.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 917 patents | US company or organization | New Brunswick, NJ | RUTGERS - THE STATE UNIVERSITY OF NEW JERSEY Federal lobbying client EXACT high confidence: identical full name and state | PTBLXML, file of 2026-09-15 |
| EMORY UNIVERSITY 646 patents | US company or organization | Atlanta, GA | Emory University College or university EXACT high confidence: identical full name and state | PTBLXML, file of 2026-09-15 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Mary M. Mouradian | Princeton, NJ | PTBLXML, file of 2026-09-15 | ||
| Stella Papa | Atlanta, GA | PTBLXML, file of 2026-09-15 | ||
| Jie Zhang | East Brunswick, NJ | PTBLXML, file of 2026-09-15 | ||
| Goichi Beck | Osaka, JP | PTBLXML, file of 2026-09-15 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| C12N | Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media | C12N15/861 | PTBLXML, file of 2026-09-15 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P25/14 | PTBLXML, file of 2026-09-15 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
No recorded assignments or security interests on file for this patent.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.